高级检索
当前位置: 首页 > 详情页

Indirect Comparison of Efficacy of Zanubrutinib Versus Orelabrutinib in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL): An Updated Analysis with Long-Term Follow up

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE ◇ CPCI(ISTP) ◇ 自然指数

单位: [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ,Beijing Canc Hosp, Beijing, Peoples R China [2]Zhengzhou Univ, Henan Canc Hosp, Dept Hematol, Canc Hosp, Zhengzhou, Peoples R China [3]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Hematol, Tongji Hosp, Wuhan, Peoples R China [4]Fujian Med Univ, Dept Hematol, Affiliated Hosp 2, Fuzhou, Peoples R China [5]Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Haihe Lab Cell Ecosyst, State Key Lab Expt Hematol,Natl Clin Res Ctr Bloo, Tianjin, Peoples R China [6]First Hosp Jilin Univ, Changchun, Peoples R China [7]Zhejiang Canc Hosp, Hangzhou, Peoples R China [8]Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China [9]Sichuan Univ, Dept Hematol, West China Hosp, Chengdu, Peoples R China [10]Nanjing Med Univ, Jiangsu Prov Hosp, Dept Hematol, Affiliated Hosp 1, Nanjing, Peoples R China [11]Southern Med Univ, Dept Hematol, Nanfang Hosp, Guangzhou, Peoples R China [12]Zhejiang Univ, Affiliated Hosp 1, Sch Med, Hangzhou, Peoples R China [13]Fudan Univ, Dept Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China [14]BeiGene Shanghai Co Ltd, Shanghai, Peoples R China [15]Peking Univ, Canc Hosp, Beijing, Peoples R China
出处:
ISSN:

摘要:
Introduction Zanubrutinib and orelabrutinib, both the next generation Bruton's tyrosine kinase inhibitors (BTKis), are used in China as treatment options for R/R MCL. A further evaluation to understand the differences between these two novel BTKis is helpful for future study. Our previously indirect comparison has suggested a favorable PFS trend in zanubrutinib over orelabrutinib in R/R MCL patients (Song Y, et al. Invest New Drugs 2023). Here, we conducted an updated analysis to indirectly compare the long-term efficacy between zanubrutinib (median follow up: 35.3 months) and orelabrutinib (median follow up: 23.8 months) in patients with R/R MCL.

语种:
WOS:
中科院(CAS)分区:
出版当年[2022]版:
大类 | 1 区 医学
小类 | 1 区 血液学
最新[2025]版:
大类 | 1 区 医学
小类 | 1 区 血液学
JCR分区:
出版当年[2021]版:
Q1 HEMATOLOGY
最新[2024]版:
Q1 HEMATOLOGY

影响因子: 最新[2024版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2020版] 出版后一年[2022版]

第一作者:
第一作者单位: [1]Peking Univ Canc Hosp & Inst, Dept Lymphoma, Key Lab Carcinogenesis & Translat Res, Minist Educ,Beijing Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:622 今日访问量:0 总访问量:452 更新日期:2025-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)